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Abstract
Background: Markers currently used to predict the likelihood 
of rapid disease progression in patients with autosomal dom-
inant polycystic kidney disease (ADPKD) are expensive and 
time consuming to assess and often have limited sensitivity. 
New, easy-to-measure markers are therefore needed that 
alone or in combination with conventional risk markers can 
predict the rate of disease progression. In the present study, 
we investigated the ability of tubular damage and inflamma-
tion markers to predict kidney function decline. Methods: At 
baseline, albumin, immunoglobulin G, kidney injury molecule 
1, β2 microglobulin (β2MG), heart-type fatty acid-binding 
protein, neutrophil gelatinase-associated lipocalin, and 
monocyte chemotactic protein-1  (MCP-1) were measured in 
24-h urine samples of patients participating in a study inves-
tigating the therapeutic efficacy of lanreotide in ADPKD. Indi-
vidual change in estimated glomerular filtration rate (eGFR) 
during follow-up was calculated using mixed-model analysis 
taking into account 13  eGFRs (chronic kidney disease EPIde-
miology) per patient. Logistic regression analysis was used to 
select urinary biomarkers that had the best association with 
rapidly progressive disease. The predictive value of these se-
lected urinary biomarkers was compared to other risk scores 
using C-statistics. Results: Included were 302 patients of 
whom 53.3% were female, with an average age of 48 ± 7 years, 
eGFR of 52 ± 12 mL/min/1.73 m2, and a height-adjusted total 
kidney volume (htTKV) of 1,082 (736–1,669) mL/m. At base-
line, all urinary damage and inflammation markers were asso-
ciated with baseline eGFR, also after adjustment for age, sex 
and baseline htTKV. For longitudinal analyses only patients 
randomized to standard care were considered (n = 152). A 
stepwise backward analysis revealed that β2MG and MCP-1 
showed the strongest association with rapidly progressive 
disease. A urinary biomarker score was created by summing 
the ranking of tertiles of β2MG and MCP-1 excretion. The pre-
dictive value of this urinary biomarker score was higher com-
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pared to that of the Mayo htTKV classification (area under the 
curve [AUC] 0.73 [0.64–0.82] vs. 0.61 [0.51–0.71], p = 0.04) and 
comparable to that of the predicting renal outcomes in  ADPKD 
score (AUC 0.73 [0.64–0.82] vs. 0.65 [0.55–0.75], p = 0.18). In a 
second independent cohort with better kidney function, sim-
ilar results were found for the urinary biomarker score. Con-
clusion: Measurement of urinary β2MG and MCP-1 excretion 
allows selection of ADPKD patients with rapidly progressive 
disease, with a predictive value comparable to or even higher 
than that of TKV or PKD mutation. Easy and inexpensive to 
measure urinary markers therefore hold promise to help pre-
dict prognosis in ADPKD. 
The Author(s). Published by S. Karger AG, Basel
Introduction
Autosomal dominant polycystic kidney disease 
 (ADPKD) is the most common inheritable kidney dis-
ease [1, 2]. The disease is characterized by the formation 
and growth of cysts in both kidneys, which results in a 
decline in glomerular filtration rate (GFR). Ultimately, 
most subjects with ADPKD will reach end-stage kidney 
disease (ESKD). However, the age at which patients with 
ADPKD will reach ESKD shows large interindividual 
variability [3], even between family members that share 
the same mutation [4]. Predicting the rate of disease 
progression has become particularly important now 
with tolvaptan the first disease-modifying treatment for 
ADPKD has become available [5, 6]. Especially patients 
with a high likelihood of rapid disease progression 
should be selected for this treatment because in such pa-
tients the benefit to risk ratio is expected to be optimal 
[7, 8].
Currently, several variables are available to predict 
the rate of disease progression in ADPKD. GFR in-
dexed for age is a strong predictor but less sensitive in 
early stages of this disease, when GFR can remain in the 
normal range, while cysts are progressively formed [3]. 
Therefore, in early-stage disease, much attention has 
been focused on total kidney volume (TKV) as a predic-
tor [3, 9, 10]. Disease progression is also influenced by 
the ADPKD genotype. Patients with a PKD1 mutation, 
especially truncating mutations, progress faster toward 
ESKD than patients with a PKD2 mutation [4, 11]. 
However, assessment of TKV and genotype is laborious 
and expensive, and their associations with the rate of 
disease progression are limited at an individual patient 
level. Therefore, new risk markers need to be developed 
that alone, or in combination with conventional risk 
markers, can predict the rate of disease progression in 
ADPKD.
Previously, we showed that easy and inexpensive to 
measure urinary inflammation and damage markers have 
the potential to predict the rate of disease progression in 
ADPKD [12]. In this study, we aimed to confirm and ex-
tend these results by investigating in an independent co-
hort of ADPKD patients with standardized follow-up 
whether urinary tubular damage and inflammation 




For this study, we included subjects who participated in the 
DIPAK-1 study, which is an investigator-driven, prospective, ran-
domized, controlled trial to test the efficacy and safety of lanreotide 
in later stage ADPKD [13]. For this trial, patients were included 
between 18 and 60 years of age, who had ADPKD based on the 
modified Ravine criteria [14], with an estimated GFR (eGFR) of 
30–60 mL/min/1.73 m2. Main exclusion criteria of the DIPAK-1 
study were bradycardia, a history of gallstones or pancreatitis, and 
diseases or medication use that could potentially affect kidney func-
tion (e.g., diabetes mellitus, or use of NSAIDs, lithium or tolvap-
tan). ClinicalTrials.gov registration is NCT01616927. The study 
was approved by the institutional review boards of each study cen-
ter. The study was performed in adherence to the Declaration of 
Helsinki, and all participants gave written informed consent.
Clinical and Biochemical Measurements
A detailed description of the study protocol has been published 
previously [13]. In short, patients were invited for a screening visit. 
When patients were eligible for study participation, a baseline visit 
took place. A day before the baseline visit, all patients collected 24-h 
urine, of which samples were stored frozen at –80  ° C until measure-
ments took place. At the day of the baseline visit, blood was drawn 
for PKD mutation analyses and for creatinine measurement. Blood 
pressure was assessed at rest in a supine position with a semi-auto-
matic, noninvasive sphygmomanometer (Dinamap) for 15 min. 
Height and weight were measured and body mass index was calcu-
lated as weight in kilograms divided by height in square meters. 
Body surface area was calculated according to the DuBois formula 
[15]. PKD mutation analysis was performed with DNA isolation us-
ing PUREGENETM nucleic acid purification chemistry on the 
 AUTOPURE LS 98 platform (Qiagen), followed by sequencing of 
amplified coding exons directly (exon 34–46), or on long-range PCR 
products (exon 1–33) [16]. After the baseline visit, patients were 
randomized to receive either standard care or lanreotide on top of 
standard care in a 1: 1 ratio. Patients collected another 24-h urine 
after 12 weeks. Blood was drawn at screening, baseline, week 12, and 
every 12 weeks thereafter until week 132 for the measurement of 
creatinine. Creatinine was measured with an enzymatic assay (iso-
tope dilution mass spectrometry traceable; Modular, Roche Diag-
nostics). GFR was estimated (eGFR) for each time point with the 
2009 chronic kidney disease EPIdemiology equation [17]. Magnetic 
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resonance imaging (MRI) was performed at baseline and weeks 120 
and 132 to assess TKV, using a standardized abdominal MRI proto-
col without the use of intravenous contrast. TKV was measured on 
T2-weighted coronal images using Analyze direct 11.0 (AnalyzeDi-
rect, Inc., Overland Park, KS, USA) by classical volumetry (i.e., man-
ual tracing) and adjusted for height TKV (htTKV). 
The frozen 24-h urine samples from baseline and 12 weeks were 
thawed, and albumin was measured as general kidney damage mark-
er; immunoglobulin G (IgG) as glomerular damage marker; β2 mi-
croglobulin (β2MG) and kidney injury molecule 1 (KIM-1) as prox-
imal tubular damage markers; heart-type fatty acid-binding protein 
(HFABP) as distal tubular damage marker; and neutrophil gelatin-
ase-associated lipocalin (NGAL) and monocyte chemotactic pro-
tein-1 (MCP-1) as inflammation markers [18–26]. Urinary albumin 
was measured with a colorimetric assay using bromocresol green 
(BCG; Sigma Aldrich Co. LLC., St. Louis, MO, USA). Urinary IgG, 
HFABP (HyTest Ltd., Turku, Finland), β2MG (Anogen-Yes Bio-
tech Laboratories Ltd., Mississauga, Canada), KIM-1, NGAL, and 
MCP-1 (R&D Systems Inc., Minneapolis, MN, USA) were measured 
by ELISA. Urine samples were diluted twice for KIM-1, β2MG, and 
MCP-1, 5 times for HFABP, and 100 times for NGAL and IgG. De-
tection limit for albumin was 5.7 µg/mL, for IgG 220 ng/mL, for 
β2MG 18 ng/mL, for KIM-1 0.087 ng/mL, for HFABP 0.38 ng/mL, 
for NGAL 22 pg/mL, and for MCP-1 0.04 ng/mL. The intra- and in-
terassay coefficients of variation were 3.8 and 6.3% for albumin, 8.4 
and 16.4% for IgG, 6.3 and 8.5% for β2MG, 7.4 and 14.5% for KIM-
1, 9.3 and 17.6% for H-FABP, 5.2 and 19.6% for NGAL, and 8.3 and 
12.7% for MCP-1, respectively. Biomarker excretions were calcu-
lated as urinary biomarker concentration × 24-h urine volume.
Statistical Analyses
Normally distributed data are expressed as mean ± SD, where-
as nonnormally distributed data are expressed as median with in-
terquartile range. Differences between patient groups were tested 
using a 2-sample t test when normally distributed or a Mann-
Whitney U test when not normally distributed. A chi-square test 
was used in case of categorical data.
We tested the associations of baseline urinary biomarker excre-
tions in all patients, and the intraindividual variation of urinary 
biomarker excretion at baseline and week 12 in patients random-
ized to standard care only with Pearson Correlation. With linear 
regression analysis, we investigated the association between base-
line urinary biomarker excretion and eGFR and htTKV cross-sec-
tionally in all patients. We tested associations crude and adjusted 
for age, sex and baseline htTKV in case of eGFR or baseline eGFR 
in case of htTKV. 
For longitudinal analyses, we only considered patients who 
were randomized to standard care as lanreotide may influence dis-
ease progression. A mixed-model repeated measures analysis was 
used to calculate annual change in eGFR per patient. Patients were 
subsequently classified as having either rapidly or slowly progres-
sive disease based on the average annual change in eGFR of the 
study population. With logistic regression analysis, we selected uri-
nary biomarkers that had the best fit for rapidly progressive disease 
when variables were taken into account that are routinely available 
in clinical care (age, sex, and baseline eGFR). Associations of indi-
vidual variables with rapidly progressive disease were tested with a 
Wald test, and the improvement of model fit was tested with the –2 
log likelihood ratio test. We first investigated the improvement of 
model fit by adding a single urinary biomarker. Next, a stepwise 
backward analysis was performed to select the best performing uri-
nary biomarkers. For this analysis, all urinary biomarkers were in-
cluded plus the fixed variables age, sex, and baseline eGFR. In each 
step, the urinary biomarker with the weakest association was ex-
cluded until only urinary biomarkers remained with an α < 0.1.
With the urinary biomarkers that were selected by the stepwise 
backward analyses, we created a urinary biomarker score by sum-
ming the ranking of tertiles of these markers (with 1 the lowest and 
3 the tertile with highest excretion). We first tested whether this 
score had an added predictive value (= area under the curve [AUC]) 
to a model with age, sex, and eGFR included using C-statistics. 
Next, we compared the predictive value of the urinary biomarker 
score to often used risk classifications for patients with ADPKD. 
We therefore classified patients according to the Mayo htTKV clas-
sification [10] and calculated the predicting renal outcomes in AD-
PKD (PROPKD) score [11]. We repeated these analyses, defining 
rapidly progressive disease based on the quartile with the most rap-
id annual change in eGFR of the study population.
Last, an independent cohort of ADPKD patients, with better 
preserved eGFR, was used to calculate a urinary biomarker score 
and we repeated our analysis using C-statistics. Details of this in-
dependent cohort and the description of the data collection have 
been published previously [12].
Analyses were performed with SPSS version 23.0 (SPSS Inc., 
Chicago, IL, USA) and STATA version 14 (Stata Corp., College 
Station, TX, USA). A two-sided p < 0.05 was considered statisti-
cally significant.
Results
Biomarker Excretions and Cross-Sectional 
Associations
For the cross-sectional analyses, we included 302 
 ADPKD patients of which 53.3% were female, who were 
48.3 ± 7.43 years of age and had an eGFR of 51.6 ± 11.6 mL/
min/1.73 m2 (Table 1). Baseline urinary biomarkers ex-
cretions are displayed in Table 2. Correlations amongst 
the urinary biomarkers were high (online suppl. Table S1; 
for all online suppl. material, see www.karger.com/
doi/10.1159/000502999), and there was low intra-indi-
vidual variation over time in all urinary biomarker excre-
tions (online suppl. Fig. S1). All urinary damage and in-
flammation markers were associated with baseline eGFR, 
also after adjustment for age, sex, and baseline htTKV 
(online suppl. Table S2, model 2), and all markers, except 
β2MG and HFABP, were associated with baseline htTKV 
after adjustment for age, sex, and eGFR (online suppl. 
Table S3, model 2).
Biomarker Excretions and Longitudinal Associations
For the longitudinal analyses, we only included pa-
tients who received standard care at follow-up (n = 152). 
The average follow-up time was 2.43 ± 0.41 years in which 
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Table 1. Baseline characteristics of ADPKD patients (n = 302)
Characteristics All patients (n = 302) Rapid progressors (n = 74) Slow progressors (n = 78) p value
Gender, female, n (%) 161 (53.3) 38 (51.4) 43 (55.1) 0.64
Age, years 48.3±7.43 47.8±6.74 49.2±7.6 0.25
Weight, kg 84.0±16.9 84.9±16.9 82.3±17.7 0.38
Height, cm 176±9.89 176±10.7 175±8.41 0.47
BSA, m2 1.99±0.22 2.00±0.22 1.97±0.22 0.32
SBP, mm Hg 133±13 135±13 132±15 0.14
DBP, mm Hg 82±9 82±10 82±10 0.80
AHT, n (%) 275 (91.1) 69 (93.2) 68 (87.2) 0.21
RAASi, n (%) 249 (82.5) 60 (81.1) 66 (84.6) 0.56
eGFR, mL/min/1.73 m2 51.6±11.6 48.8±11.2 54.8±11.3 0.001
htTKV, mL/m 1,082 (736–1,669) 1,095 (832–1,786) 952 (652–1,505) 0.06
PKD mutation, n (%) 0.08
PKD1 truncating 139 (46.0) 41 (55.4) 30 (38.5)
PKD1 nontruncating 79 (26.1) 20 (27.1) 21 (26.9)
PKD2 59 (19.6) 8 (10.8) 18 (23.0)
No mutation detected 15 (5.0) 2 (2.7) 7 (9.0)
Missing 10 (3.3) 3 (4.1) 2 (2.6)
Variables are presented as mean ± SD or as median (IQR) in case of nonnormal distribution.
p values for fast versus slow progressors are calculated using independent-sample t test in case of normal distribution, Mann-Whit-
ney U in case of nonnormal distribution, and chi-square in case of categorical data. Rapid and slow progressors were defined as patients 
with an annual change in eGFR less than or equal to –3.5 or greater than –3.5 mL/min/1.73 m2, respectively.
ADPKD, autosomal dominant polycystic kidney disease; BSA, body surface area; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; AHT, anti-hypertensive therapy; RAASi, RAAS inhibitors; eGFR, estimated glomerular filtration rate; htTKV, height-adjusted 
total kidney volume; PKD, polycystic kidney disease.
Table 2. Baseline urinary biomarker excretion (n = 302)
Urinary biomarker All patients (n = 302) Rapid progressors (n = 74) Slow progressors (n = 78) p value
General, mg/24 h
Albumin 184.3 (144.4–240.3) 196.3 (154.4–248.1) 174.8 (132.7–211.7) 0.02
Glomerular, mg/24 h
IgG 6.03 (3.59–10.82) 7.18 (4.51–11.74) 5.04 (3.38–9.52) 0.02
Proximal tubular, µg/24 h 
β2MG 191.2 (120.9–258.4) 247.0 (168.8–307.8) 183.1 (87.7–239.0) <0.001
KIM-1 0.97 (0.67–1.35) 1.06 (0.73–1.51) 0.88 (0.61–1.19) 0.04
Distal tubular, µg/24 h 
HFABP 17.6 (12.2–25.4) 21.9 (13.4–31.6) 17.0 (12.4–22.8) 0.005
Inflammatory
NGAL, µg/24 h 39.4 (24.5–63.8) 50.6 (29.9–76.7) 34.8 (23.4–55.1) 0.007
MCP-1, ng/24 h 517.9 (317.7–809.4) 612.5 (421.0–944.9) 374.8 (240.1–684.2) 0.001
Variables are presented as median (IQR) and p values were calculated for rapid versus slow progressors with a Mann-Whitney U test. 
Rapid and slow progressors were defined as patients with an annual change in eGFR less than or equal to –3.5 or greater than –3.5 mL/
min/1.73 m2, respectively.
IgG, immunoglobulin G; β2MG, β2 microglobulin; KIM-1, kidney injury molecule 1; HFABP, heart-type fatty acid-binding protein; 
NGAL, neutrophil gelatinase-associated lipocalin; MCP-1, monocyte chemotactic protein 1.
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patients had an annual change in eGFR of –3.52 ± 2.01 mL/
min/1.73 m2 per year and an annual change in htTKV of 
6.06 ± 2.20% per year.
Online supplementary Table S4 shows results of a linear 
regression analysis with annual change in eGFR as depen-
dent variable and the urinary biomarkers as independent 
variable. Crude, all markers were associated with annual 
change in eGFR. After adjustment for age, sex, baseline 
eGFR, htTKV, and PKD mutation, only β2MG, KIM-1, 
HFABP, and MCP-1 remained significantly associated (on-
line suppl. Table S4, model 3). None of the biomarkers was 
associated with annual change in htTKV, neither crude nor 
after adjustment for covariates (online suppl. Table S5).
Biomarker Excretions and Prediction of Rapidly 
Progressive Disease
To select patients for treatment in clinical practice, it 
is important to distinguish patients with rapidly from 
slowly progressive disease. Patients were divided in either 
having rapidly (n = 74) or slowly progressive disease (n = 
78) based on the mean annual change in eGFR of the pop-
ulation (less than or equal to –3.5 or greater than –3.5 mL/
min/1.73 m2 per year). Other large-scale clinical trials re-
ported a similar value for mean annual kidney function 
decline in patients with ADPKD [5, 6, 27, 28]. Baseline 
characteristics were comparable between rapid and slow 
progressors except for eGFR and TKV (Table 1). All uri-
nary biomarker excretions were higher in fast compared 
to slow progressors (Table 2).
Since in routine clinical practice information on age, 
sex, and eGFR is always available, we investigated which 
of the markers had the strongest association with rapidly 
progressive disease when added to these variables (Table 
3). When adding β2MG, KIM-1, HFABP, NGAL, or 
MCP-1 (model 2), the fit of the model improved signifi-
cantly. When performing a stepwise backward analysis 
testing all urinary biomarkers, with age, sex, and eGFR as 
fixed variables, only β2MG and MCP-1 remained associ-
ated (model 3) and improved the model fit compared to 
model 1 and 2. The fit of the model improved only further 
when PKD mutation was added (p = 0.045) but not when 
baseline htTKV was added (p = 0.84).
Table 3. Model predicting rapidly versus slowly progressive disease (annual change in eGFR less than or equal to or greater than –3.5 mL/




(as model 1 + single biomarker)
Model 3
(stepwise backward)
OR [95% CI] p value OR [95% CI] p value OR [95% CI] p value
–2 log likelihood ratio 189 NA 179**
Age (per 10 years) 0.59 [0.36–0.98] 0.04 – – 0.81 [0.46–1.42] 0.46
Gender, female 0.84 [0.54–2.16] 0.84 – – 1.37 [0.65–2.87] 0.41
eGFR (per 10 mL/min/1.73 m2) 0.57 [0.41–0.80] 0.001 – – 0.62 [0.43–0.88] 0.008
Albumin (per SD) 1.25 [0.86–2.81] 0.24
IgG (per SD) 0.92 [0.61–1.40] 0.70
β2MG (per SD) 1.61* [1.08–2.40] 0.02 1.49 [0.99–2.23] 0.055
KIM-1 (per SD) 1.46* [0.99–2.14] 0.06
HFABP (per SD) 1.64* [0.94–2.86] 0.08
NGAL (per SD) 1.61* [1.01–2.59] 0.048
MCP-1 (per SD) 1.63* [1.09–2.44] 0.02 1.52 [1.01–2.28] 0.047* –2 log likelihood ratio p < 0.05 compared to model 1.** –2 log likelihood ratio p = 0.007 compared to model 1 and p = 0.04 and p = 0.049 compared to model 2 with β2MG or MCP-1, 
respectively.
ORs and p values were calculated using logistic regression analysis. Dependent variable is rapid versus slow disease progression (an-
nual change in eGFR less than or equal to –3.5 versus greater than –3.5 mL/min/1.73 m2).
Model 1: Age, female sex, and eGFR.
Model 2: Age, female sex, eGFR, and one of the urinary biomarkers.
Model 3: Age, female sex, eGFR, urinary β2MG, and MCP-1 excretion.
eGFR, estimated glomerular filtration rate; IgG, immunoglobulin G; β2MG, β2 microglobulin; KIM-1, kidney injury molecule 1; 
HFABP, heart-type fatty acid-binding protein; NGAL, neutrophil gelatinase-associated lipocalin; MCP-1, monocyte chemotactic pro-
tein 1.
Messchendorp et al.Am J Nephrol 2019;50:375–385380
DOI: 10.1159/000502999
Predictive Value of an Urinary Biomarker Score
Figure 1 displays the proportion of patients with fast 
or slow progressing disease and annual change in eGFR 
according to tertiles of β2MG excretion or MCP-1 excre-
tion. Patients in the lowest tertile of β2MG or MCP-1 ex-
cretion had a significantly lower rate of eGFR decline 
compared to patients in the 2 higher tertiles. By summing 
the ranking of tertiles of these markers (with 1 the lowest 
and 3 the highest excretion), a urinary biomarker score 
was created with values ranging from 2 to 6. With a lower 
score, a slower decline in eGFR was observed (Fig. 2). Pa-
tients with the lowest score of 2 had a significantly slower 
rate of eGFR decline compared to patients with a score of 
5 or 6.
The urinary biomarker score improved the predictive 
value of a model with age, sex, and eGFR included (AUC 
0.67 [0.60–0.75] vs. 0.73 [0.65–0.81], p = 0.049; Fig. 3a). 






























































































































Fig. 1. Proportion of patients with rapidly progressive disease (a) 
and annual change in eGFR (b) according to tertiles of biomarker 
excretion. Rapid and slow progressors were defined as patients 
with an annual change in eGFR less than or equal to –3.5 or great-
er than –3.5 mL/min/1.73 m2, respectively. Differences in propor-
tion across tertiles of β2MG excretion p = 0.002 and across tertiles 
of MCP-1 excretion p = 0.004. β2MG, β2 microglobulin; MCP-1, 
monocyte chemotactic protein-1; eGFR, estimated glomerular fil-
tration rate.
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urinary biomarker score with other, often used risk clas-
sifications for patients with ADPKD. We therefore clas-
sified patients according to their Mayo htTKV class and 
calculated the PROPKD score. We had htTKV available 
for 150 patients from which 5 (3.3%) were classified as 
having atypical ADPKD. For patients with typical 
 ADPKD, 2.1% were classified as class 1A, 15.2% 1B, 37.9% 
1C, 28.3% 1D, and 16.6% 1E. Online supplementary Fig-
ure S2 represents the proportion of patients with rapidly 






































































Fast progressor Slow progressor
a b
Fig. 2. Proportion of patients with rapidly progressive disease (a) 
and annual change in eGFR (b) according to a urinary biomarker 
score, calculated by combining tertiles of β2MG excretion and 
MCP-1 excretion. Rapid and slow progressors were defined as pa-
tients with an annual change in eGFR less than or equal to –3.5 or 
greater than –3.5 mL/min/1.73 m2, respectively. Differences in 
proportion across urinary biomarker score p < 0.001. eGFR, esti-
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Fig. 3. Added predictive value of urinary biomarker score on top 
of age, sex, and eGFR (a; n = 146; AUC 0.67 [0.58–0.75] vs. 0.73 
[0.65–0.81], p = 0.049) and predictive value of urinary biomarker 
score compared to Mayo htTKV classification or PROPKD score 
(b; n = 115; AUC 0.73 [0.64–0.82] vs. 0.61 [0.51–0.71], p = 0.04 or 
0.65 [0.55–0.75], p = 0.18 respectively). eGFR, estimated glomeru-
lar filtration rate; htTKV, height-adjusted total kidney volume; 
PROPKD, predicting renal outcomes in ADPKD.
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tients with typical ADPKD. The PROPKD score was 
available for 123 patients and 33.3% of these patients were 
classified as having a low risk (PROPKD score ≤3), 44.7% 
an intermediate risk (PROPKD score 4–6), and 22.0% a 
high risk (PROPKD score 7–9). Online supplementary 
Figure S3 shows the proportion of patients with rapidly 
progressive disease according to this score. In our pa-
tients, the predictive value of the urinary biomarker score 
was higher than that of the Mayo htTKV classification 
(AUC 0.73 [0.64–0.82] vs. 0.61 [0.51–0.71], p = 0.04). The 
predictive value of the urinary biomarker score was also 
higher compared to that of the PROPKD score, but this 
did not reach statistical significance (AUC 0.73 [0.64–
0.82] vs. 0.65 [0.55–0.75], p = 0.18; Fig. 3b). Of note, the 
Mayo htTKV classification or the PROPKD score did not 
improve the prediction of rapidly progressive disease on 
top of age, sex, eGFR, and the urinary biomarker score 
(AUC 0.75 [0.66–0.84] vs. 0.80 [0.72–0.89], p = 0.07 and 
vs. 0.80 [0.72–0.89], p = 0.12).
We repeated these analyses, defining rapid disease 
progression as the subjects belonging to the quartile with 
the most rapid annual change in eGFR (annual change in 
eGFR less than or equal to –4.9 mL/min/1.73 m2). With 
this definition, 38 patients were classified as having rap-
idly and 114 patients as having slowly progressive disease. 
The urinary biomarker score again improved the predic-
tive value of a model with age, sex, and eGFR included 
(AUC 0.79 [0.67–0.90] vs. 0.69 [0.57–0.81], respectively, 
p = 0.02). Furthermore, the predictive value of the bio-
marker score was higher than that of the Mayo htTKV 
classification (AUC 0.75 [0.63–0.87] vs. 0.58 [0.47–0.70], 
p = 0.02) and also compared to that of the PROPKD score, 
although this did again not reach formal statistical sig-
nificance (AUC 0.75 [0.63–0.87] vs. 0.60 [0.48–0.73], p = 
0.09).
Performance of Urinary Biomarker Score in an 
Independent Cohort
We used another cohort of 104 patients with early-
stage ADPKD [12] to test the predictive value of β2MG 
and MCP-1. Nine patients were excluded, who were also 
included in above analyses or had missing values, leaving 
95 patients for analysis, of which 41.1% were female (age 
39.6 ± 11.1 years, eGFR 78.6 ± 29.6 mL/min/1.73 m2, and 
htTKV 852 (510–1,212) mL/m; online suppl. Table S6). 
During a follow-up time of 3.8 ± 1.2 years, annual change 
in eGFR was –3.21 ± 3.12 mL/min/1.73 m2 per year. We 
subsequently created tertiles of urinary excretion of 
β2MG and MCP-1 (< 99, 99–400, > 400 μg/24 h and < 582, 
582–910, > 910 ng/24 h, respectively). Online supplemen-
tary Figure S4 displays the proportion of patients of this 
independent cohort with rapidly or slowly progres-
sive  disease (annual change in eGFR of less than or 
equal to –3.5 mL/min/1.73 m2 or greater than –3.5 mL/
min/1.73 m2, respectively) and annual change in eGFR 
according to β2MG and MCP-1 excretion biomarker 
score. This score improved the predictive value of a mod-
el with age, sex, and eGFR included (AUC 0.66 [0.54–
0.77] vs. 0.77 [0.68– 0.86], p = 0.02). The urinary bio-
marker score performed equally compared to the Mayo 
htTKV classification in this population (AUC 0.72 [0.61–
0.82] vs. 0.75 [0.64–0.85], p = 0.64). No data were avail-
able to calculate the PROPKD score, but information on 
PKD mutation was available. The biomarker score tended 
to have a higher predictive value compared to PKD muta-
tion, although this did not reach statistical significance 
(0.73 [0.63–0.84] vs. 0.60 [0.49–0.71], p = 0.11).
Discussion 
In the present study, we showed that the urinary excre-
tion of in particular β2MG and MCP-1 predicts rapidly 
progressive disease in patients with ADPKD independent 
of TKV and PKD mutation. In our study population, the 
predictive value of a urinary biomarker score (based on 
tertiles of β2MG and MCP-1 excretion) was higher com-
pared to that of the Mayo htTKV classification and equal 
to that of the PROPKD score.
We measured urinary tubular damage markers that 
represent inflammation and damage to different parts of 
the nephron. It is likely that in a chronic disease like AD-
PKD, these processes occur simultaneously. Therefore, 
>1 urinary marker may have the ability to predict rapidly 
progressive disease and the predictive ability may also 
vary per patient. In this study, we chose to select those 
urinary markers that predict rapidly progressive disease 
in the overall study population when added to variables 
that are always available in routine clinical care (age, sex, 
and eGFR). When performing these analyses, urinary 
β2MG and MCP-1 showed the strongest associations 
with rapidly progressive disease, and these markers pre-
dicted rapidly progressive disease beyond age, sex, and 
eGFR, especially when added simultaneously.
In a previous study, we already showed that especially 
β2MG and MCP-1 had strong associations with annual 
change in eGFR [12], and the present study therefore cor-
roborates these previous results. As β2MG reflects proxi-
mal tubular damage and MCP-1 reflects inflammation, 
these results suggest that the proximal tubule and inflam-
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mation are involved in the pathophysiology of ADPKD. 
Importantly, however, we caution against overinterpreta-
tion of our findings because one should be aware of the 
strengths and limitations of the various assays. The fact 
that associations between some markers and rapidly pro-
gressive disease are stronger should not lead to conclu-
sions which parts of the renal tubule are more involved 
with cystogenesis. These results may in part be based on 
technical aspects, such as higher intra- and interassay co-
efficient of variation of the assay or less stability of the 
marker during frozen storage [29, 30].
Although TKV has repeatedly been shown to be a good 
predictor of the rate of eGFR decline, in our study it did 
not predict rapidly progressive disease when age, sex, 
eGFR, urinary β2MG, and MCP-1 were taken into ac-
count. Moreover, we demonstrated that a score based on 
urinary biomarkers alone had a higher predictive value 
for rapidly progressive disease than the Mayo htTKV 
classification. It could be that in our study, TKV was a less 
predictive biomarker because our study population was 
selected based on impaired eGFR, that is, it was enriched 
for subjects with rapidly progressive disease. Indeed, rel-
atively few patients were classified as having Mayo htTKV 
class 1A/B, and class 1C/D/E could not discriminate be-
tween patients with rapidly or slowly progressive disease 
(online suppl. Fig. S2). We repeated our analyses in an 
independent, unselected, observational cohort. In this co-
hort, we found that a score based on urinary biomarkers 
had a similar predictive value compared to the Mayo 
 htTKV classification. Similarly, the PROPKD score (a 
score based on sex, the occurrence of hypertension and 
urological events before the age of 35, and PKD mutation) 
had an equal predictive value compared to the urinary 
biomarker score. 
Our urinary biomarker score consists of 5 classes. Fig-
ure 2b shows a graded association with rate of eGFR de-
cline. These classes could be combined to a score with, for 
example, only 3 classes indicating low, intermediate, and 
high risk for rapidly progressive disease to make the score 
more clinically applicable. Similarly, for clinical purpos-
es, the Mayo htTKV classification is divided in classes 
1A/B, 1C, and 1D/E and the PROPKD score in a score of 
0–3, 4–6, and 7–9, corresponding to low, intermediate, 
and high risk of reaching ESKD [11, 31].
These data indicate that although urinary biomarkers 
have an equal predictive value to htTKV class and geno-
type, optimal risk prediction may be achieved when in-
formation is taken into account on multiple variables, 
among which urinary biomarkers as well as htTKV and/
or genotype. In routine clinical care, however, informa-
tion on htTKV or PKD mutation is often not available 
because as yet they are relatively laborious and expensive 
to measure. Furthermore, with the PROPKD score, pa-
tients cannot be classified when they are younger than 
35 years and not yet developed clinical events or when no 
mutation is detected. With a urinary biomarker score, 
that is relatively easy and inexpensive to obtain, all pa-
tients, also with earlier stage disease, can be classified. 
Furthermore, these urinary biomarkers are not ADPKD 
specific like htTKV or PKD mutation. This could be an 
advantage rather than a disadvantage because they may 
also reflect any damage on top of that caused by ADPKD, 
for instance due to environmental factors, which may 
lead to a more precise prediction of the rate of disease 
progression. Therefore, urinary biomarkers may be used 
as alternative to the more expensive and laborious volu-
metry and PKD mutation analysis for risk prediction, but 
when other measures are available, they should also be 
taken into account. 
Another advantage of urinary biomarkers is that they 
may rapidly respond to treatment, in contrast to TKV or 
PKD mutation, and thereby serve as a surrogate of treat-
ment response. We already showed in previous research 
that certain urinary biomarkers declined in response to 
3 weeks of tolvaptan treatment [32]. Change in urinary 
excretion of tubular damage markers holds therefore 
promise to indicate treatment response in a certain pa-
tient. Future studies should investigate whether treat-
ment-induced short-term changes in urinary tubular 
damage markers are associated with long-term outcome.
The present study has limitations. First, our cohort 
was selected for inclusion in a clinical trial with specific 
inclusion and exclusion criteria. We therefore did not 
include patients over the entire spectrum of the disease, 
but with later stage ADPKD [12], and consequently, 
there were not much differences between baseline char-
acteristics of rapid and slow progressors. In this popula-
tion with later stage ADPKD, eGFR indexed for age is 
already informative for risk prediction in contrast to pa-
tients with earlier stage ADPKD because eGFR can re-
main fairly stable, while cysts are already formed. De-
spite this, the urinary biomarkers were added to risk 
prediction in this population with later stage ADPKD. 
In a population where GFR indexed for age is less infor-
mative, the urinary biomarkers may then be of even 
more value. For these reasons, we also investigated the 
predictive value of a urinary biomarker score in an in-
dependent observational cohort that encompasses the 
entire spectrum of the disease, among which also earlier 
stage ADPKD, and found similar results. Second, for the 
Messchendorp et al.Am J Nephrol 2019;50:375–385384
DOI: 10.1159/000502999
measurement of urinary biomarkers, we used samples 
that were stored frozen, which may have influenced the 
results. However, previous research showed that β2MG 
and MCP-1 remain fairly stable during prolonged fro-
zen storage [33, 34]. It should be noted that the absolute 
values of the biomarker excretions hold for the present 
study as there may be differences between assays that are 
commercially available in other studies. In the future, 
the available assays need to be optimized and standard-
ized to define specific cutoff values with high sensitivity 
and specificity before these biomarkers can be imple-
mented in clinical care. Third, we defined rapid disease 
progression based on the mean kidney function decline 
in the study population, and results may be different 
when another definition is used. We therefore also de-
fined rapid disease progression based on the quartile 
with the most rapid kidney function decline of the study 
population (annual change in eGFR of less than or equal 
to –4.9 mL/min/1.73 m2) and found essentially similar 
results.
Strengths of this study are that we included ADPKD 
patients from which standardized follow-up data were 
available. Based on 13 fasting creatinine measurements 
over time, we were able to calculate reliable individual 
eGFR slopes using mixed models. Some assume that 
eGFR trajectories are not linear over time in patients with 
ADPKD, with eGFR that can remain fairly stable at young 
age [35]. In this study, however, we investigated patients 
with later stage disease. In such patients, eGFR slopes are 
reliable. In addition, we had data available to calculate the 
Mayo htTKV class and PROPKD score to allow compar-
isons, and we were able to validate our findings in an in-
dependent cohort. Last, all patients collected 24-h urine 
for biomarker assessment, which, due to the circadian 
rhythm in urinary excretion of these markers, is assumed 
to be better than spot urines that are used in most other 
studies [36]. 
In conclusion, urinary β2MG and MCP-1 excretion 
have the ability to select patients with rapidly progressive 
ADPKD, with a predictive value comparable to or even 
higher than that of TKV and PKD mutation. Easy and in-
expensive to measure urinary markers therefore hold 
promise to help identify patients with rapidly progressive 
disease, for instance, to be treated with disease-modifying 
agents.
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